GlassScriptPhysician profile
Sheila W Gorman
NPI 1467467993
$2,201.15
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $468 · 2020: $187 · 2021: $721 · 2022: $590 · 2023: $220 · 2024: $14.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $234.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $337.40 | 2021-2023 | |
| Amgen INC. | $262.33 | 2019-2023 | Tezspire |
| Pfizer INC. | $150.62 | 2019-2023 | |
| Lilly USA, LLC | $148.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $127.03 | 2019-2022 | |
| Amarin Pharma, INC. | $115.01 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $113.32 | 2019-2023 | |
| Astellas Pharma US INC | $102.17 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.23 | 2021-2022 | |
| Novo Nordisk INC | $87.53 | 2019-2023 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $76.05 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $62.84 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $58.05 | 2022 | |
| Sanofi-Aventis U.S. LLC | $51.39 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $47.72 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $46.54 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.36 | 2023-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $36.52 | 2019-2023 | Fasenra |
| Abbott Laboratories | $29.82 | 2022 | |
| Eisai INC. | $28.85 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.70 | 2019-2022 | |
| Dexcom, INC. | $24.29 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.92 | 2022 | |
| Biogen, INC. | $21.33 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.42 | 2021 | |
| Shire North American Group INC | $15.89 | 2019 | |
| Smith+Nephew, INC. | $15.22 | 2020 | |
| Sumitomo Pharma America, INC. | $15.15 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $13.41 | 2019 | |
| Allergan, INC. | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Gorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.